up to date,
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GFM.
Esamfyc,
T2E2A3 Antiagregantes en pacientes con IRC aumenta riesgo de hemorragia mayor, valorar benefic Vía @rincondesisifo http://t.co/Z…
Asociación Argentina de Farmacéuticos de Hospital,
Antiplatelet agents for chronic kidney disease
Centre for Evidence-based Medicine,
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008834.pub2/abstract;jsessionid=0109CC9BD99F9F24A89992F5F9C9E2BF.d04t03